One instrument, multiple jobs: analysis of biomolecules using Q-TOF HRMS
This webinar introduces the application of Q-TOF HRMS in the analysis of biomolecules with a wide range of molecular weights. The first section demonstrates the comparable sensitivity, linearity and multiplexity between HRMS and triple quadrupole when quantitating a panel of peptide hormones (MW 1 kDa to 9.4 kDa). The advantages of HRMS over triple quadrupole in targeted quantitation are also discussed.
The second section illustrates how Q-TOF is used to perform native MS analysis without instrumentation modifications. With optimized instrumental settings, noncovalent protein complexes up to 450 kDa can be characterized.
What will you learn?
- Sensitivity, selectivity, linearity and multiplexity of Q-TOF HRMS in targeted peptide quantitation
- The advantages and disadvantages of Q-TOF HRMS for quantitative purpose when compared with triple quadrupole MS
- How to optimize instrument settings of Q-TOF HRMS to perform native MS analysis without hardware modifications
- How in vitro noncovalent protein complexes are characterized by native MS
- The technical limitations of commercially available Q-TOF HRMS to analyze macromolecules in the native state
Who may this interest?
- Scientists seeking to develop LC−MS assays for PK/PD analysis with high selectivity and sensitivity
- Lab managers who consider investing a versatile mass spectrometer capable of analyzing a wide range of biomolecules
- Researchers with limited instrument availability but who are interested in analyzing noncovalent protein-protein interactions or characterizing protein complexes by native MS
Speaker
Zhuo Chen
Exploratory Biomaker Assay Sr. Analyst
GSK (PA, USA)
Zhuo Chen received his BS and MS degree in Peking University (Beijing, China) and then pursued a PhD degree at Brown University (RI, USA) focusing on mass spectrometry-based proteomics. After graduating from Brown in 2016, Zhuo joined GSK as a GSK/Waters joint postdoctoral fellow. In the department of bioanalysis, immunogenicity and biomarkers (BIB), his work focused on developing LC−MS assays to quantitate protein therapeutics and biomarkers. Since switching to a full-time GSK employee of BIB in 2017, he took more responsibility for supporting GLP-regulated PK/PD assays. Zhuo has published five bioanalytical papers since 2019 and delivered oral presentations at ASMS and CPSA annual conferences.
In association with
